Pamiparib
- Generic Name
- Pamiparib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15FN4O
- CAS Number
- 1446261-44-4
- Unique Ingredient Identifier
- 8375F9S90C
- Background
Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).
- Indication
用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Conditions
- Interventions
- Drug: Albumin-Bound PaclitaxelDrug: OtherDrug: EpirubicinDrug: GemcitabineDrug: VinorelbineDrug: CisplatinDrug: IrinotecanDrug: FluorouracilDrug: NivolumabDrug: PembrolizumabDrug: DurvalumabDrug: AtezolizumabDrug: SintilimabDrug: TislelizumabDrug: CamrelizumabDrug: ToripalimabDrug: SerplulimabDrug: AdebrelimabDrug: EnvafolimabDrug: OsimertinibDrug: AlectinibDrug: VemurafenibDrug: PamiparibDrug: PyrotinibDrug: ImatinibDrug: PalbociclibDrug: SavolitinibDrug: Entrectinib
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 40
- Registration Number
- NCT06387056
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Bai-Rong Xia
- Target Recruit Count
- 37
- Registration Number
- NCT05652283
- Locations
- 🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 30
- Registration Number
- NCT05526924
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 38
- Registration Number
- NCT05494580
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05489926
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT05483543
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Hongqian Guo
- Target Recruit Count
- 30
- Registration Number
- NCT05376722
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
🇨🇳The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT05327621
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT05044871
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.